



RNS Number : 5800I  
Roquefort Therapeutics PLC  
05 December 2022

5 December 2022

**Roquefort Therapeutics plc**  
("Roquefort Therapeutics" or the "Company")

**Presentation of Midkine Oligonucleotide Program at the European Society  
of Medical Oncology  
Asia conference**

*Abstract accepted at leading biological therapeutics conference*

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, is pleased to announce that its Midkine program was presented on 3 December 2022 at the European Society of Medical Oncology Asia conference in Singapore. The presentation reported that the lead oligonucleotide program showed >90% efficacy in human cancer cells (at the mRNA level), reduced functional Midkine and is ready for efficacy testing as a novel anticancer medicine.

The poster and abstract were embargoed until the presentation at the conference:

<https://www.esmo.org/meeting-calendar/esmo-asia-congress-2022>

**-Ends-**

**Enquiries:**

**Roquefort Therapeutics plc**

Stephen West (Chairman) / Ajan Reginald  
(CEO)

+44 (0)20 3918  
8633

**Hybridan LLP (Joint Broker)**

Claire Louise Noyce

+44 (0)203 764  
2341

**Optiva Securities Limited (Joint Broker)**

Christian Dennis

+44 (0)20 3411  
1881

**Buchanan (Public Relations)**

Ben Romney / Jamie Hooper / George Beale

+44 (0)20 7466  
5000

LEI: 254900P4SISIWOR9RH34

**About Roquefort Therapeutics**

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.

Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lynamid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Roquefort Therapeutics' portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of:

- Midkine antibodies with significant *in vivo* efficacy and toxicology studies;
- Midkine RNA therapeutics with novel anti-cancer gene editing action;
- MK cell therapy with direct and NK-mediated anti-cancer action; and
- siRNA targeting novel STAT-6 target in solid tumours showing significant *in vivo* efficacy.

For further information on Roquefort Therapeutics, please visit [www.roquefortplc.com](http://www.roquefortplc.com) and @RoquefortTherap on Twitter.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an

orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAGZMGZRKDGZZG

Anonymous (not verified)

Presentation of Midkine Oligonucleotide Program

33153599

A

Mon, 12/05/2022 - 08:07

LSE RNS

Company Announcement - General

ROQ